NCT03346135View on ClinicalTrials.gov

Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

July 17, 2019

Primary Completion Date

November 17, 2025

Study Completion Date

November 17, 2025

Conditions
Plasma Cell MyelomaSecondary Amyloidosis
Interventions
PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo standard of care ASCT with a conditioning regimen of melphalan

BIOLOGICAL

Daratumumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Melphalan

Undergo standard of care ASCT with a conditioning regimen of melphalan

Trial Locations (2)

37203

Sarah Cannon Cancer Center, Nashville

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT03346135 - Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma | Biotech Hunter | Biotech Hunter